Výsledky vyhledávání

Akademický článek

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Autor: Rui Cai, Flore Decuypere, Pierre Chevalier, Martin Desseilles, Martin Lambert, Eric Fakra, Antonie Wimmer, Pascal Guillon, Stefan Pype, Annabelle Godet, Valeria Borgmeier

Publikováno v: BMC Psychiatry, Vol 22, Iss 1, Pp 1-12 (2022)

Abstract Background Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients. We aim to assess risk factors of trea

Externí odkaz: https://doaj.org/article/9f20bf6e76d946e3a4fef99fa7866759

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate

Autor: Rebekka Lencer, Maria Paz Garcia-Portilla, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller, Katalin Pungor

Publikováno v: Comprehensive Psychiatry, Vol 107, Iss , Pp 152233- (2021)

Rationale: Reducing the frequency of long-acting injectable antipsychotic medication may reduce carer burden. Objectives: To evaluate the impact of reduced frequency of long-acting injectable antipsychotic medication on carer burden in stable patient

Externí odkaz: https://doaj.org/article/51ab9250a21847269b9ad3fa8a1bb76a

Zobrazit plný text záznamu

Akademický článek

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in france, germany and belgium – a retrospective database study

Autor: R. Cai, F. Decuypere, P. Chevalier, A. Wimmer, P. Guillon, S. Pype, A. Godet, V. Timtschenko

Publikováno v: European Psychiatry, Vol 64, Pp S164-S164 (2021)

Introduction Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients. Objectives To assess risk factors of treat

Externí odkaz: https://doaj.org/article/dc8d1ba5dc12468598814172f28cfef1

Zobrazit plný text záznamu

Akademický článek

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia

Autor: Brasso C, Bellino S, Bozzatello P, Montemagni C, Rocca P

Publikováno v: Neuropsychiatric Disease and Treatment, Vol Volume 13, Pp 2767-2779 (2017)

Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Paola Rocca Department of Neurosciences “Rita Levi Montalcini”, University of Turin, Turin, Italy Aims: Paliperidone palmitate 3-month (PP3M) represents a new long-acting inj

Externí odkaz: https://doaj.org/article/d415268b471b4f449e3ef95504a3d5bb

Zobrazit plný text záznamu

Akademický článek

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study

Autor: Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ

Publikováno v: Neuropsychiatric Disease and Treatment, Vol Volume 13, Pp 2193-2207 (2017)

Adam J Savitz,1 Haiyan Xu,2 Srihari Gopal,1 Isaac Nuamah,2 Paulien Ravenstijn,3 David Hough,1 Maju Mathews,4 Yu Feng,5 Lu Yu,6 Masayoshi Takahashi,7 Dennis Liu,8 Gang Wang,9 Jin-Sang Yoon,10 Jiahn-Jyh Chen11 1Department of Central Nervous System, 2De

Externí odkaz: https://doaj.org/article/84695b1947674cf9a5c2df66088c4d0b

Zobrazit plný text záznamu

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Autor: Cai, Rui, Decuypere, Flore, Chevalier, Pierre, Desseilles, Martin, Lambert, Martin, Fakra, Eric, Wimmer, Antonie, Guillon, Pascal, Pype, Stefan, Godet, Annabelle, Borgmeier, Valeria

Publikováno v: Cai, R, Decuypere, F, Chevalier, P, Desseilles, M, Lambert, M, Fakra, E, Wimmer, A, Guillon, P, Pype, S, Godet, A & Borgmeier, V 2022, ' Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium ', BMC Psychiatry, vol. 22, no. 1, 382 . https://doi.org/10.1186/s12888-022-03914-2

Background Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients. We aim to assess risk factors of treatment dis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::618316e6b605a254a3d0ab59aadcba7d
https://doi.org/10.1186/s12888-022-03914-2

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání